Skip to main content

Advertisement

Table 2 Organ involvement at onset (%)

From: High-dose intravenous immunoglobulin therapy for eosinophilic granulomatosis with polyangiitis

  EGPA patients treated with IVIG within the period of initial treatment (n = 10) EGPA patients treated with IVIG on relapse after remission (n = 7) P
Asthma 100 100 NS*
Paranasal sinusitis 90 85.7 NS*
Multiple polyneuropathy 100 100 NS*
Minimum MMT score, mean ± 1 SD 3.1 ± 0.9 4.1 ± 0.7 0.05
Pulmonary infiltrates 80 85.7 NS*
Myocardial involvement 50 100 0.05*
Gastrointestinal tract 80 100 NS*
Liver, gall bladder, pancreas 16.7 30 NS*
Renal involvement 20 28.5 NS*
  Proteinuria 50 42.8 NS*
  Eosinophils in urine 28.6 40 NS*
  Nephritis or nephrosis 10 14.3 NS*
Skin involvement 90 100 NS*
Arthritis 40 42.8 NS*
Myalgia 40 28.5 NS*
Central nervous system involvement 30 28.5 NS*
Number of organs involved per patient‡‡, mean ± 1 SD 5.7 ± 1.1 6.3 ± 2.1 NS
FFS2009 1.5 ± 1.0 1.4 ± 1.0 NS
  1. EGPA, eosinophilic granulomatosis with polyangiitis; FFS, five-factor score; IVIG, intravenous immunoglobulin; MMT, manual muscle test; NS, not significant.
  2. All values are expressed as means ± 1 SD.
  3. Values of P ≤ 0.05 were considered statistically significant.
  4. Two-way ANOVA with repeated measures between groups.
  5. *Chi-squared testing revealed no significant differences between groups.
  6. Renal involvement including proteinuria or eosinophils in urine or glomerular nephritis or nephrosis or renal dysfunction.
  7. ‡‡Cumulative organ involvement excluding asthma and sinusitis.